IMCRImmunocore Holdings plc
Price
-9.8%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Nothing alarming, growing in the filings, the market undecided.
We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging our proprietary, flexible, off-the-shelf ImmTAX® (Immune mobilizing monoclonal TCRs Against X disease) platform, we are developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and earlier pre-clinical programs across three therapeutic areas.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Immunocore Holdings plc (IMCR) reported revenue of $116M in Q2 2026 (quarter ended Jun 30, 2026), up 18% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $808K. For the full year FY2025, revenue was $400M (+29% year on year) and net income −$36M. Its largest product in Q2 2024 (quarter ended Jun 30, 2024) was Sale Of Therapies at $75M, 100% of the disclosed total, well ahead of Collaboration at 0.1%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- May 6, 2026Immunocore reports first quarter financial results and provides a business update.Earnings release · press release
- Feb 25, 2026Immunocore reports fourth quarter and full year 2025 financial results and provides a business update.Earnings release · press release
- Jan 30, 2026On January 27, 2026, David Berman notified Immunocore Holdings plc (the “Company”) of his decision to resign as Head of Research & Development of the Company, effective as of February 27, 2026, in order to pursue another opportunity.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2024 · $75.4MThe company’s own SEC segment disclosure.
- Sale Of Therapies$75.3M100%
- Collaboration$53.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.